Agenus (AGEN)
(Real Time Quote from BATS)
$13.24 USD
+1.12 (9.24%)
Updated May 1, 2024 04:00 PM ET
After-Market: $13.24 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.24 USD
+1.12 (9.24%)
Updated May 1, 2024 04:00 PM ET
After-Market: $13.24 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
Agenus (AGEN) Sharpens Focus on Drug Development Programs
by Zacks Equity Research
We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
Agenus (AGEN) Reports Narrower-than-Expected Q4 Loss
by Zacks Equity Research
Agenus reported narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of 33 cents per share, while the company reported a loss of 30 cents.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
by Zacks Equity Research
Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
by Zacks Equity Research
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.